Mental Health Research Institute, University of Melbourne
Welcome,         Profile    Billing    Logout  
 5 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bateman, Randall
DIAN-TU, NCT06384573: Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer's Disease

Not yet recruiting
3
65
Europe, US, RoW
lecanemab, BAN2401
Washington University School of Medicine, Alzheimer's Association, Eisai Inc.
Alzheimer's Disease, Dementia, Alzheimer's Disease, Familial
11/29
11/29
DIAN-TU, NCT06424236: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Terminated
2/3
73
Europe, Canada, US, RoW
Gantenerumab, RO4909832
Washington University School of Medicine, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA)
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
08/23
11/23
DIAN-TU, NCT05269394: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Recruiting
2/3
168
Europe, Canada, Japan, US, RoW
E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc.
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
07/27
10/27
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001

Checkmark From DIAN-TU trial
Feb 2020 - Feb 2020: From DIAN-TU trial
Checkmark Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Feb 2020 - Feb 2020: Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Checkmark DIAN TU: N=210
More
Recruiting
2/3
490
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
10/27
10/27
NCT03938870: CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease

Completed
N/A
96
US
L-Leucine 13C6
Washington University School of Medicine, BrightFocus Foundation, National Institutes of Health (NIH)
Alzheimer's Disease, Brain Diseases, Central Nervous System Diseases, Delirium, Dementia, Amnestic, Cognitive Disorders, Dementia, Mental Disorders, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies
07/23
07/23
SEABIRD, NCT03899844: Study to Evaluate Amyloid in Blood and Imaging Related to Dementia

Completed
N/A
1122
US
Blood collection, PiB PET/MRI, and cognitive testing
Washington University School of Medicine
Alzheimer Disease, Alzheimer Dementia
01/24
01/24
DIAN, NCT00869817: Dominantly Inherited Alzheimer Network

Recruiting
N/A
700
Europe, Canada, Japan, US, RoW
Washington University School of Medicine, National Institute on Aging (NIA)
Alzheimer's Disease
07/25
07/25
Masters, Colin
DIAN-TU, NCT05269394: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation

Recruiting
2/3
168
Europe, Canada, Japan, US, RoW
E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Alzheimer's Association, National Institute on Aging (NIA), Accelerating Medicines Partnership (AMP), Eisai Inc.
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
07/27
10/27
DIAN-TU, NCT01760005 / 2013-000307-17: Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol -001

Checkmark From DIAN-TU trial
Feb 2020 - Feb 2020: From DIAN-TU trial
Checkmark Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Feb 2020 - Feb 2020: Top-line data from DIAN-TU trial in rare inherited form of Alzheimer's disease
Checkmark DIAN TU: N=210
More
Recruiting
2/3
490
Europe, Canada, Japan, US, RoW
Gantenerumab, RO4909832, Solanezumab, LY2062430, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, BAN2401, Matching Placebo (E2814)
Washington University School of Medicine, Eli Lilly and Company, Hoffmann-La Roche, Alzheimer's Association, National Institute on Aging (NIA), Avid Radiopharmaceuticals, Accelerating Medicines Partnership (AMP), Eisai Inc., Janssen, LP
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
10/27
10/27
Vidaurre, Lesley
No trials found

Download Options